Related references
Note: Only part of the references are listed.Fetal Brain Lesions in Tuberous Sclerosis Complex: TORC1 Activation and Inflammation
Avanita S. Prabowo et al.
BRAIN PATHOLOGY (2013)
Resveratrol pre-treatment reduces early inflammatory responses induced by status epilepticus via mTOR signaling
Sheng-jun Wang et al.
BRAIN RESEARCH (2013)
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
David Neal Franz et al.
LANCET (2013)
Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma
Darcy A. Krueger et al.
NEUROLOGY (2013)
mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy
Emilio Russo et al.
NEUROPHARMACOLOGY (2013)
Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of Tuberous Sclerosis Complex
Marco Cambiaghi et al.
NEUROPHARMACOLOGY (2013)
Vigabatrin Inhibits Seizures and mTOR Pathway Activation in a Mouse Model of Tuberous Sclerosis Complex
Bo Zhang et al.
PLOS ONE (2013)
Detection of Human Papillomavirus in Human Focal Cortical Dysplasia Type IIB
Julie Chen et al.
ANNALS OF NEUROLOGY (2012)
Mammalian Target of Rapamycin (mTOR) Inhibition: Potential for Antiseizure, Antiepileptogenic, and Epileptostatic Therapy
Robin C. C. Ryther et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2012)
Identification of new epilepsy treatments: Issues in preclinical methodology
Aristea S. Galanopoulou et al.
EPILEPSIA (2012)
Finding a better drug for epilepsy: The mTOR pathway as an antiepileptogenic target
Aristea S. Galanopoulou et al.
EPILEPSIA (2012)
Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood-brain barrier leakage but not microglia activation
Erwin A. van Vliet et al.
EPILEPSIA (2012)
Rapamycin has age-, treatment paradigm-, and model-specific anticonvulsant effects and modulates neuropeptide Y expression in rats
Tamar Chachua et al.
EPILEPSIA (2012)
Pentylenetetrazole-induced seizures cause acute, but not chronic, mTOR pathway activation in rat
Bo Zhang et al.
EPILEPSIA (2012)
Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex
Marta Perek-Polnik et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2012)
Hemimegalencephaly: foetal tauopathy with mTOR hyperactivation and neuronal lipidosis
Harvey Sarnat et al.
FOLIA NEUROPATHOLOGICA (2012)
The differential effects of prenatal and/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex
Sharon W. Way et al.
HUMAN MOLECULAR GENETICS (2012)
Combination therapy targeting Akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact in mice
Juyeon Park et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2012)
Multiple Roles for Mammalian Target of Rapamycin Signaling in Both Glutamatergic and GABAergic Synaptic Transmission
Matthew C. Weston et al.
JOURNAL OF NEUROSCIENCE (2012)
Impaired Autophagy in Neurons after Disinhibition of Mammalian Target of Rapamycin and Its Contribution to Epileptogenesis
John McMahon et al.
JOURNAL OF NEUROSCIENCE (2012)
The mTOR Signaling Pathway in the Brain: Focus on Epilepsy and Epileptogenesis
Emilio Russo et al.
MOLECULAR NEUROBIOLOGY (2012)
De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly
Jeong Ho Lee et al.
NATURE GENETICS (2012)
Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin
Robert P. Carson et al.
NEUROBIOLOGY OF DISEASE (2012)
Post-treatment with rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy
Anna Sliwa et al.
NEUROSCIENCE LETTERS (2012)
The Interaction between Early Life Epilepsy and Autistic-Like Behavioral Consequences: A Role for the Mammalian Target of Rapamycin (mTOR) Pathway
Delia M. Talos et al.
PLOS ONE (2012)
The mTOR Inhibitor Rapamycin Has Limited Acute Anticonvulsant Effects in Mice
Adam L. Hartman et al.
PLOS ONE (2012)
Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex
Atsushi Sato et al.
NATURE COMMUNICATIONS (2012)
Sustained Activation of mTOR Pathway in Embryonic Neural Stem Cells Leads to Development of Tuberous Sclerosis Complex-Associated Lesions
Laura Magri et al.
CELL STEM CELL (2011)
Inhibition of the mammalian target of rapamycin blocks epilepsy progression in NS-Pten conditional knockout mice
C. Nicole Sunnen et al.
EPILEPSIA (2011)
Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis
Raffaella Cusmai et al.
EPILEPSY & BEHAVIOR (2011)
Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex
Stefanie Anderl et al.
HUMAN MOLECULAR GENETICS (2011)
Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features
Robert Pilarski et al.
JOURNAL OF MEDICAL GENETICS (2011)
Rapamycin Suppresses Mossy Fiber Sprouting But Not Seizure Frequency in a Mouse Model of Temporal Lobe Epilepsy
Paul S. Buckmaster et al.
JOURNAL OF NEUROSCIENCE (2011)
Rapamycin passes the torch: a new generation of mTOR inhibitors
Don Benjamin et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
A pulse rapamycin therapy for infantile spasms and associated cognitive decline
Emmanuel Raffo et al.
NEUROBIOLOGY OF DISEASE (2011)
Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis
Sharon S. McDaniel et al.
NEUROSCIENCE LETTERS (2011)
Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex
June Goto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner
Sutapa Banerjee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders
Dan Ehninger et al.
TRENDS IN MOLECULAR MEDICINE (2011)
mTOR: A pathogenic signaling pathway in developmental brain malformations
Peter B. Crino
TRENDS IN MOLECULAR MEDICINE (2011)
Focal Cortical Dysplasias: clinical implication of neuropathological classification systems
Roberto Spreafico et al.
ACTA NEUROPATHOLOGICA (2010)
Activation of autophagy and Akt/CREB signaling play an equivalent role in the neuroprotective effect of rapamycin in neonatal hypoxia-ischemia
Silvia Carloni et al.
AUTOPHAGY (2010)
Evaluation of development-specific targets for antiepileptogenic therapy using rapid kindling
Raman Sankar et al.
EPILEPSIA (2010)
Early control of seizures improves long-term outcome in children with tuberous sclerosis complex
Roberta Bombardieri et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2010)
STRADα deficiency results in aberrant mTORC1 signaling during corticogenesis in humans and mice
Ksenia A. Orlova et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy
Xiaoxing Huang et al.
NEUROBIOLOGY OF DISEASE (2010)
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis.
Darcy A. Krueger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Mammalian target of rapamycin Hitting the bull's-eye for neurological disorders
Zhao Zhong Chong et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2010)
mTOR signaling: At the crossroads of plasticity, memory and disease
Charles A. Hoeffer et al.
TRENDS IN NEUROSCIENCES (2010)
Involvement of mTOR kinase in cytokine-dependent microglial activation and cell proliferation
Cinzia Dello Russo et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Recent advances in neurobiology of Tuberous Sclerosis Complex
Valerio Napolioni et al.
BRAIN & DEVELOPMENT (2009)
Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia
M. Cecilia Ljungberg et al.
DISEASE MODELS & MECHANISMS (2009)
Focal cortical dysplasia: A genotype-phenotype analysis of polymorphisms and mutations in the TSC genes
Christoph Gumbinger et al.
EPILEPSIA (2009)
Rapamycin Reduces Seizure Frequency in Tuberous Sclerosis Complex
Jennifer Muncy et al.
JOURNAL OF CHILD NEUROLOGY (2009)
Hamartin Variants That Are Frequent in Focal Dysplasias and Cortical Tubers Have Reduced Tuberin Binding and Aberrant Subcellular Distribution In Vitro
Celine Lugnier et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2009)
Inhibition of the Mammalian Target of Rapamycin Signaling Pathway Suppresses Dentate Granule Cell Axon Sprouting in a Rodent Model of Temporal Lobe Epilepsy
Paul S. Buckmaster et al.
JOURNAL OF NEUROSCIENCE (2009)
The Mammalian Target of Rapamycin Signaling Pathway Mediates Epileptogenesis in a Model of Temporal Lobe Epilepsy
Ling-Hui Zeng et al.
JOURNAL OF NEUROSCIENCE (2009)
Pharmacological Inhibition of mTORC1 Suppresses Anatomical, Cellular, and Behavioral Abnormalities in Neural-Specific Pten Knock-Out Mice
Jing Zhou et al.
JOURNAL OF NEUROSCIENCE (2009)
Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex
Ling-Hui Zeng et al.
ANNALS OF NEUROLOGY (2008)
Role of mTOR in physiology and pathology of the nervous system
Lukasz Swiech et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2008)
Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: Effects on mTORC1 and Akt signaling lead to improved survival and function
Lynsey Meikle et al.
JOURNAL OF NEUROSCIENCE (2008)
Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis
Dan Ehninger et al.
NATURE MEDICINE (2008)
Polyhydramnios, megalencephaty and symptomatic epilepsy caused by a homozygous 7-kilobase deletion in LYK5
Erik G. Puffenberger et al.
BRAIN (2007)
Rapamycin is a neuroprotective treatment for traumatic brain injury
S. Erlich et al.
NEUROBIOLOGY OF DISEASE (2007)
Activity- and mTOR-dependent suppression of Kv1.1 channel mRNA translation in dendrites
Kimberly F. Raab-Graham et al.
SCIENCE (2006)
A role for the mTOR pathway in surface expression of AMPA receptors
Yanling Wang et al.
NEUROSCIENCE LETTERS (2006)
Impaired synaptic plasticity in a rat model of tuberous sclerosis
C von der Brelie et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2006)
Control of dendritic arborization by the phosphoinositide-3'-kinase-Akt-mammalian target of rapamycin pathway
J Jaworski et al.
JOURNAL OF NEUROSCIENCE (2005)
Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2
SF Tavazoie et al.
NATURE NEUROSCIENCE (2005)
Intractable seizures in tuberous sclerosis complex: From molecular pathogenesis to the rationale for treatment
P Curatolo et al.
JOURNAL OF CHILD NEUROLOGY (2005)
Dysregulation of the TSC-mTOR pathway in human disease
K Inoki et al.
NATURE GENETICS (2005)
mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo
CH Kwon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Characteristics of epilepsy in focal cortical dysplasia in infancy
A Lortie et al.
EPILEPSY RESEARCH (2002)
Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease
CH Kwon et al.
NATURE GENETICS (2001)
Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease
SA Backman et al.
NATURE GENETICS (2001)
Share Paper
